

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock code: 0460)

Change of Joint Company Secretary and Authorised Representatives

The board of directors (the “Board”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “Company”) announces that Mr. Ngai Wai Fung (“Mr. Ngai”) has tendered his resignation (the “Resignation”) as the joint company secretary, authorised representative under the Rules (the “Listing Rules”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and authorised representative under the Hong Kong Companies Ordinance of the Company with effect from 20 November 2010 due to his personal pursuits and development. Mr. Ngai confirmed that he has no disagreement with the Board and there are no circumstances relating to his Resignation which need to be brought to the attention of the Stock Exchange and/or the shareholders of the Company.

Reference is made to a waiver granted to the Company by the Stock Exchange dated 12 October 2010 (the “Waiver”) from strict compliance with Rule 8.17 of the Listing Rules for an initial period of three years from the date of listing on the condition that the Company engages Mr. Ngai, who possesses the requisite qualifications under Rule 8.17 of the Listing Rules, as a joint company secretary to assist Mr. Choi Yiau Chong (“Mr. Choi”), the other joint company secretary who is not ordinarily resident in Hong Kong and does not possess the qualifications under Rule 8.17 of the Listing Rules, so as to enable him to acquire the “relevant experience” within the meaning of Rule 8.17(3) of the Listing Rules and to discharge the functions as a joint company secretary. Upon the resignation of Mr. Ngai on 20 November 2010, the Waiver has ended at the even date.

The Board announces that Ms. Ma Sau Kuen Gloria (“Ms. Ma”) has been appointed in replacement of Mr. Ngai as the joint company secretary of the Company with effect from 20 November 2010. The Stock Exchange has granted a new waiver to the Company from strict compliance with the requirements under Rule 8.17 of the Listing Rules for a period from 20 November 2010 to 27 October 2013 (i.e. the remaining period of three years for the Waiver) in relation to Mr. Choi’s eligibility to act as the joint company secretary on the condition that Mr. Choi would be assisted by Ms. Ma to acquire the “relevant experience” within the meaning of Rule 8.17(3) of the Listing Rules and to discharge his duties as joint company secretary of the Company.

The Board is also pleased to announce that Ms. Ma has been appointed as the authorised representative under the Listing Rules and authorised representative under the Hong Kong Companies Ordinance of the Company with effect from 20 November 2010.

Ms. Ma has almost 30 years of experience in corporate secretarial work that include acting as company secretary for companies listed on the Stock Exchange and setting up companies in different jurisdictions such as Hong Kong, Cayman Islands and British Virgin Islands. She also has extensive knowledge and experience in corporate restructuring and legal compliance issues.

Ms. Ma is a director and Head of Registration and Compliance Services of KCS Hong Kong Limited, a corporate secretarial and accounting services provider in Hong Kong. She holds a master degree in Business Administration from the University of Strathclyde, Scotland and is a Fellow member of both the Hong Kong Institute of Chartered Secretaries and the Institute of Chartered Secretaries and Administrators in the United Kingdom.

The Board would like to thank Mr. Ngai for his contribution and welcome Ms. Ma to the Company.

By Order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman

Hong Kong, 25 November 2010

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng and Mr. Meng Xianhui, our non-executive directors are Dr. Zhang Jionglong, Mr. Homer Sun and Mr. Eddy Huang and our independent non-executive director are Mr. Patrick Sun, Mr. Bai Huiliang and Mr. Xu Kangsen.